Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSK131 in MTAP-deficient advanced solid tumors
NCT07288957Phase 1Recruiting
- Sponsor
- Abbisko Therapeutics
- Start
- Jul 2025
- Primary completion
- Dec 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of ABSK131 in solid tumor, sponsored by Abbisko Therapeutics. Primary endpoints: Incidence of Dose-Limiting Toxicities at 21 days, Adverse Events at 30 months and 2 more. Started Jul 2025; status: recruiting.
02
Drugs
ABSK131
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07288957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07288957.